Last updated: August 1, 2026
Colistin sulfate is an established polymyxin antibiotic used mainly in veterinary medicine and, in some markets, for oral or topical human applications. Its commercial position is materially different from intravenous colistimethate sodium, the prodrug used for systemic treatment of multidrug-resistant Gram-negative infections. Public clinical-development activity for colistin sulfate is limited, no major late-stage human trial program is evident, and the active pharmaceutical ingredient has no meaningful modern composition-of-matter patent barrier. Market growth is likely to come from resistant-infection demand, veterinary formulations and regional supply expansion rather than from a new patented human product.
What is colistin sulfate and how does it compare with colistimethate sodium?
Colistin sulfate is the sulfate salt of colistin, a mixture of polymyxin E components, principally colistin A and colistin B. It is microbiologically active in its administered form. Colistimethate sodium, also called colistin methanesulfonate, is a less-toxic prodrug that converts to colistin in vivo.
| Attribute |
Colistin sulfate |
Colistimethate sodium |
| Chemical status |
Active polymyxin salt |
Prodrug of colistin |
| Main use |
Veterinary, oral or topical regional human products |
Intravenous, inhaled and sometimes intrathecal human therapy |
| Systemic human use |
Limited by toxicity and pharmacokinetics |
Established hospital use for resistant infections |
| Renal toxicity risk |
Material if systemically absorbed |
Material, but dosing is controlled through prodrug administration |
| FDA systemic approval |
No prominent FDA-approved systemic sulfate product |
Coly-Mycin M and other colistimethate products |
| Patent position |
Legacy compound and formulation rights largely expired |
Legacy product rights largely expired; newer delivery systems may have separate patents |
| Biosimilar relevance |
None; small molecule |
None; small molecule |
The distinction matters commercially. Market reports that combine "colistin," "colistimethate sodium" and "polymyxin antibiotics" can materially overstate the addressable market for colistin sulfate itself.
What clinical trials are evaluating colistin sulfate?
Human clinical-trial activity for colistin sulfate is sparse compared with trials involving colistimethate sodium. The dominant research questions concern colistin exposure, nephrotoxicity, pulmonary delivery, pharmacokinetics and combination therapy. These studies generally use colistimethate sodium rather than colistin sulfate.
The current clinical profile is:
| Development area |
Colistin sulfate status |
Commercial implication |
| Intravenous treatment of MDR Gram-negative infections |
No established late-stage sulfate program |
Low probability of near-term innovator launch |
| Inhaled treatment for cystic fibrosis or ventilator-associated infection |
Research has focused mainly on inhaled colistimethate sodium |
Sulfate has limited differentiation |
| Oral gastrointestinal decolonization or infection |
Regionally used, but limited modern pivotal-trial activity |
Potential niche opportunity |
| Veterinary anti-infective use |
Established and commercially active |
Largest practical sulfate demand segment |
| Combination therapy |
Mostly investigated with other polymyxins or colistimethate products |
Supports formulation and stewardship research, not a new sulfate franchise |
| Resistance suppression |
Important research topic, but not a sulfate-specific approval pathway |
Regulatory value depends on new clinical evidence |
The FDA-approved Coly-Mycin M label identifies colistimethate sodium, not colistin sulfate, as the systemic product and warns about nephrotoxicity, neurotoxicity and neuromuscular blockade (U.S. Food and Drug Administration [FDA], 2019). EMA guidance also treats colistin products as high-risk medicines requiring careful dose expression, pharmacokinetic control and renal monitoring (European Medicines Agency [EMA], 2016).
ClinicalTrials.gov records should be screened separately for "colistin sulfate," "colistin," "colistimethate sodium" and "polymyxin E." A search limited to the sulfate salt can substantially undercount the wider colistin clinical-development landscape, while a search for colistin alone can overstate sulfate-specific activity.
What is the FDA regulatory status of colistin sulfate?
Colistin sulfate does not have the same U.S. regulatory position as colistimethate sodium. The principal FDA-approved systemic product is colistimethate sodium injection, marketed historically as Coly-Mycin M. Colistin sulfate is not a major listed active ingredient in the FDA’s current human systemic antibiotic product landscape.
FDA approval and dosage forms
Potential regulatory routes for a colistin sulfate product include:
- An abbreviated new drug application for a qualifying reference product, if an approved U.S. reference exists.
- A 505(b)(2) application for a differentiated dosage form, route or delivery system.
- A full new drug application for a new clinical indication, dosing regimen or combination.
- An animal-drug pathway for veterinary products.
A sulfate product would face specific questions involving systemic exposure, conversion or absorption, impurity control, polymyxin component ratios, renal safety and dose nomenclature. The regulatory pathway is more straightforward for veterinary oral or feed-related products than for systemic human use.
What is the Orange Book status of colistin sulfate?
Colistin sulfate has no widely recognized U.S. Orange Book patent estate comparable to newer branded antibiotics. The Orange Book listings associated with colistin products relate primarily to colistimethate sodium and legacy product entries, not to a broad, current sulfate-specific exclusivity program.
| Exclusivity category |
Colistin sulfate position |
| New chemical entity exclusivity |
Expired or unavailable for the legacy active |
| Orphan-drug exclusivity |
No established current sulfate indication |
| Pediatric exclusivity |
No material sulfate-specific period identified |
| Patent term extension |
No relevant modern sulfate franchise identified |
| Listed formulation patents |
Limited and generally legacy or jurisdiction-specific |
| Biosimilar exclusivity |
Not applicable |
| Generic substitution |
Depends on product, route and local regulatory classification |
The absence of a current Orange Book barrier does not eliminate regulatory risk. A new manufacturer could still face development costs for bioequivalence, chemistry and manufacturing controls, sterile production, impurity specifications and clinical safety.
When does colistin sulfate lose exclusivity?
The foundational intellectual-property rights for colistin and colistin sulfate are decades old and do not create a current global exclusivity period. New patents could still cover:
- A specific sulfate polymorph or particle-size distribution.
- A purified colistin A or colistin B composition.
- A fixed-dose combination.
- A controlled-release oral dosage form.
- A lung-targeted or inhaled formulation.
- A manufacturing process that improves yield or reduces impurities.
- A veterinary premix, soluble powder or water-soluble formulation.
- A new method of treating a defined resistant bacterial infection.
Such patents would protect the new technical feature, not the underlying colistin molecule. Patent duration would generally run 20 years from the earliest effective nonprovisional filing date, subject to jurisdictional adjustments.
How strong is the patent estate for colistin sulfate?
The legacy molecule has weak patent protection. A newly developed formulation could have moderate protection if it demonstrates a measurable pharmacokinetic, stability, safety or manufacturing advantage. Method-of-use claims are more vulnerable because polymyxins are already known for treating resistant Gram-negative infections and because obviousness and written-description challenges would be likely.
A defensible sulfate patent strategy would require more than a routine salt change. Stronger claims would typically depend on:
- Defined composition and impurity limits.
- Reproducible pharmaceutical performance.
- Reduced renal or neurologic toxicity.
- Improved local delivery with lower systemic exposure.
- A clinically supported dosing regimen.
- Manufacturing data showing a non-obvious process advantage.
What patent litigation and Paragraph IV challenges affect colistin sulfate?
No major recent U.S. Paragraph IV campaign centered specifically on colistin sulfate has shaped the public market. The likely reason is commercial scale. Colistin products are generally low-cost, mature anti-infectives, and the commercial return may not justify expensive patent litigation unless a sponsor introduces a differentiated delivery system.
Potential litigation would most likely involve:
- Non-infringement of formulation claims.
- Invalidity based on prior art for salt formation or dosage design.
- Lack of enablement for broad toxicity-reduction claims.
- Bioequivalence disputes involving colistin exposure.
- Product-by-process claims.
- Veterinary label and manufacturing patents.
Settlement agreements are not a central feature of the publicly visible sulfate market. The absence of a major settlement landscape reduces litigation-based launch uncertainty but also indicates limited commercial investment in branded sulfate products.
What formulations are protected or commercially relevant?
The main commercial formulation categories are oral solid products, oral solutions or powders, topical preparations, veterinary premixes and water-soluble veterinary products. Systemic human formulations are generally associated with colistimethate sodium rather than sulfate.
Human formulation opportunities
The most credible human opportunities are local-delivery products that limit systemic exposure:
- Inhaled formulations for chronic airway infection.
- Gastrointestinal formulations for selective decontamination.
- Topical products for localized infection.
- Combination products designed to reduce resistance emergence.
- Modified-release products for intestinal delivery.
Each route requires distinct clinical and regulatory evidence. A product that is not systemically absorbed may avoid some systemic toxicity concerns but must demonstrate local efficacy, microbiological control and acceptable resistance effects.
Veterinary formulations
Veterinary demand remains the most important commercial driver for colistin sulfate. Products include oral powders, premixes and drinking-water formulations used against Enterobacterales and other susceptible organisms. Regulatory pressure is significant because WHO classifies colistin as a highest-priority critically important antimicrobial for human medicine (World Health Organization [WHO], 2019).
European restrictions on veterinary colistin use have reduced demand in some markets. China and other high-volume livestock markets have also implemented controls, although the scale and enforcement of restrictions vary by country.
How large is the colistin sulfate market?
Public market reports usually estimate a broader "colistin market" that includes colistimethate sodium, sulfate products, veterinary products and sometimes polymyxin B. Those estimates are not reliable proxies for colistin sulfate revenue.
A more useful market structure is:
| Segment |
2024 outlook |
2030 direction |
| Human systemic colistin sulfate |
Very small |
Flat unless a new delivery product succeeds |
| Human inhaled or local sulfate products |
Niche |
Moderate upside with clinical differentiation |
| Veterinary sulfate products |
Largest sulfate segment |
Flat to declining in tightly regulated markets |
| API and contract manufacturing |
Active but price-sensitive |
Stable, with regional supply shifts |
| Combination or specialty formulations |
Small base |
Highest percentage growth potential |
Analyst projection
A reasonable base-case projection for the global colistin sulfate market, excluding colistimethate sodium and polymyxin B, is low-single-digit annual growth through 2030. The market is likely to remain a low-value generic and veterinary-led segment rather than become a major branded pharmaceutical category.
| Scenario |
2024-2030 annual growth |
Principal assumptions |
| Downside |
-3% to -1% |
Expanded veterinary restrictions, stewardship pressure and price erosion |
| Base case |
1% to 3% |
Stable veterinary demand, modest API growth and limited specialty formulations |
| Upside |
4% to 7% |
Successful local-delivery product, new regional approvals or renewed MDR demand |
The upside case requires product-level innovation. Higher infection incidence alone is unlikely to generate strong sulfate revenue because hospitals increasingly manage colistin through controlled colistimethate sodium protocols and reserve use for infections with few alternatives.
Which companies compete in colistin sulfate?
Competition is fragmented across generic pharmaceutical manufacturers, veterinary companies, API suppliers and regional distributors. The most relevant competitive variables are:
- API purity and colistin A/B ratio.
- Compliance with current good manufacturing practice.
- Sterile or nonsterile production capability.
- Veterinary registration coverage.
- Ability to supply regulated markets.
- Batch consistency and impurity control.
- Price and supply reliability.
The market does not have a single dominant global colistin sulfate brand. Supplier concentration can still create procurement risk because polymyxin manufacturing is technically demanding and dependent on fermentation, purification and quality-control capacity.
What manufacturing and IP barriers exist?
The core manufacturing barrier is process control, not basic molecule ownership. Colistin is produced through fermentation and requires purification of a complex mixture of related polymyxin components. Key controls include:
- Fermentation yield.
- Component ratio consistency.
- Removal of endotoxins and process impurities.
- Residual solvent and elemental impurity limits.
- Microbial limits for oral or veterinary products.
- Sterility assurance for parenteral products.
- Stability under storage and distribution conditions.
For human products, the largest barrier is clinical safety. Renal toxicity, neurotoxicity, dose-conversion errors and variable exposure can delay development even when the underlying antimicrobial activity is well established.
What generic launch scenarios exist for colistin sulfate?
A generic or regional manufacturer has three practical launch paths:
- Launch a conventional oral or veterinary sulfate product in a market with an established reference product.
- Develop a 505(b)(2)-type local-delivery product with differentiated exposure or convenience.
- Supply API and finished dosage forms to existing veterinary or hospital-product companies.
The conventional generic path has the lowest technical risk but the highest price pressure. A differentiated inhaled or controlled-release product has greater value potential but requires clinical evidence and may attract formulation patents.
Is there biosimilar risk for colistin sulfate?
Biosimilar risk is not applicable because colistin sulfate is a chemically defined small-molecule antibiotic, not a biologic. The relevant competitive threat is generic entry, therapeutic substitution with colistimethate sodium or polymyxin B, and replacement by newer agents such as cefiderocol, newer beta-lactam/beta-lactamase inhibitor combinations and other drugs active against resistant Gram-negative pathogens.
How does colistin sulfate compare with newer antibiotics?
Colistin sulfate has the advantage of low acquisition cost and long clinical experience. Its disadvantages include toxicity, narrow therapeutic margins, resistance concerns and limited innovation potential.
| Product class |
Cost position |
Safety |
Resistance role |
Patent opportunity |
| Colistin sulfate |
Low |
Poorer |
Salvage or veterinary use |
Limited |
| Colistimethate sodium |
Low to moderate |
Poorer than newer agents |
Hospital salvage therapy |
Limited except delivery systems |
| Polymyxin B |
Low to moderate |
Nephrotoxic |
Salvage therapy |
Limited |
| New beta-lactam combinations |
Higher |
Generally improved |
Targeted MDR treatment |
Stronger |
| Cefiderocol |
Higher |
Differentiated clinical use |
Resistant Gram-negative infections |
Meaningful remaining commercial protection in some markets |
Key takeaways
- Colistin sulfate is a mature polymyxin salt with limited modern human clinical-development activity.
- Most systemic human research concerns colistimethate sodium, not sulfate.
- The legacy molecule has no meaningful current composition-of-matter exclusivity.
- Colistin sulfate has no major biosimilar issue and no prominent current Paragraph IV litigation campaign.
- Veterinary formulations remain the principal commercial segment, but stewardship restrictions create long-term volume pressure.
- The strongest growth opportunity is a differentiated local-delivery or controlled-exposure formulation.
- The base-case market outlook through 2030 is low-single-digit growth, with downside risk from veterinary restrictions and generic price erosion.
- Manufacturing quality, impurity control and supply reliability are more important barriers than legacy patent ownership.
FAQs about colistin sulfate
Is colistin sulfate approved for intravenous use in the United States?
The principal FDA-approved systemic colistin product is colistimethate sodium, not colistin sulfate. U.S. regulatory status depends on the specific product, route and indication.
Is colistin sulfate the same as colistimethate sodium?
No. Colistin sulfate is an active salt, while colistimethate sodium is a prodrug used in systemic and inhaled human products.
Does colistin sulfate have a long-term patent life?
The underlying active ingredient is long off patent. Only newer formulations, manufacturing methods or treatment methods could support meaningful remaining patent protection.
Why is colistin sulfate still used in veterinary medicine?
It is inexpensive, active against susceptible Gram-negative pathogens and available in oral veterinary dosage forms. Its use is increasingly restricted because colistin is critically important to human medicine.
Could a new colistin sulfate inhaled product obtain regulatory exclusivity?
Yes. A differentiated inhaled product could potentially obtain regulatory exclusivity or patent protection if it meets applicable clinical, formulation and safety requirements. The protection would attach to the new product, not to the old sulfate molecule.
References
-
European Medicines Agency. (2016). Use of colistin products in humans and animals within the European Union: Development of resistance and possible impact on human and animal health. EMA.
-
U.S. Food and Drug Administration. (2019). Coly-Mycin M parenteral: Colistimethate sodium prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
World Health Organization. (2019). Critically important antimicrobials for human medicine, 6th revision. WHO.
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov search records for colistin, colistin sulfate and colistimethate sodium. National Institutes of Health.
